About the Report
- The oncolytic viruses therapy landscape contains numerous viral therapies and technologies, making for an exciting and promising future, especially with the exciting results from DELYTACT® and ONCOS-102.
- Transgene modifications continue to be the most common changes to OVs, most of which are added to enhance anti-tumor immune responses.
- The second half of 2022 is sure to be engaging, with results from clinically active phase 1, 1/2 and 2 expected.
- We hope that you find this H1 landscape review report useful and insightful.
Find out more
This insight and data is part of the subscription to Beacon Oncolytic Viruses.
Speak with our Team
Our dedicated team can help you with questions by showing you how this insight and data is collated on Beacon.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements